Rebecca L. Siegel, MPH, lead author of the “Colorectal Cancer Statistics, 2026” report recently published in CA: A Cancer ...

Michael Bernstein, MD, discusses how AI-assisted radiology workflows affect liability, automation bias, and patient safety in diagnostic imaging. As artificial intelligence (AI) becomes more embedded ...

CMS is pursuing empiric fee-schedule accuracy in original Medicare (eg, validating procedure time assumptions) while rapidly expanding MSSP and CMMI pathways to move beyond unmanaged fee-for-service.

Cost-related delayed or forgone care was associated with 78% higher odds of an ED visit among Latino adults, indicating downstream acute-care reliance when timely outpatient care is unaffordable. ED ...

Peter Staley at CROI 2026 on defending 45 years of HIV progress: how clinicians, payers, and advocates can resist—quietly or publicly—and why it matters.

In ‘Evaluating Transthyretin Stabilizers and Silencers in ATTR-CM,’ our panel delves into the segment by asking Dr. Alexander to explain the differences between transthyretin ...

MajesTEC-9 supports moving teclistamab earlier in myeloma treatment, with robust PFS and OS gains over standard care in the second-line setting, notes Roberto Mina, MD. AJMC: Given the 71% reduction ...

Long-term ATTR-CM trial data show durable benefits with early tafamidis or acoramidis, fewer deaths/hospitalizations, and manageable safety.

The University of Michigan celebrated the 21st anniversary of its annual V-BID Summit on March 11, 2026, highlighting pathways to improve value-based insurance design and ensuring ...

Epcoritamab plus R-DHAX/C achieved 79% ORR and 69% CR, with median 1.4 months to response and early activity evident by the first week-6 assessment. Over half of patients reached ASCT after ...

From a study that analyzed the therapeutic dilemma of treating acute leukemia (AL) during pregnancy and the delicate balance of improving maternal and fetal outcomes, investigators determined that ...

Intranasal epinephrine was developed to provide needle-free, on-demand rescue therapy for CSU flares, addressing limitations of systemic options such as glucocorticoids and their adverse-effect burden ...